Welcome to our dedicated page for Sensei Biotherapeutics news (Ticker: $SNSE), a resource for investors and traders seeking the latest updates and insights on Sensei Biotherapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Sensei Biotherapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Sensei Biotherapeutics's position in the market.
Sensei Biotherapeutics, a clinical stage immuno-oncology company, announced its participation in the Jefferies Global Healthcare Conference. The event will take place in New York on June 6, 2024, at 8:30 a.m. ET. John Celebi, President and CEO, is set to present. The presentation will be webcast live on the investors section of Sensei's website, with a replay available for 90 days.
Sensei Biotherapeutics has released promising data from the Phase 1 dose escalation study of their human monoclonal antibody, SNS-101, targeting the immune checkpoint VISTA. The study shows that SNS-101 is well-tolerated with no dose-limiting toxicities and demonstrates signs of clinical activity, particularly in tumor types typically unresponsive to PD-1 therapies.
Among the 34 patients, promising results were observed in those with microsatellite stable (MSS) endometrial cancer, MSS colorectal cancer, pembrolizumab-resistant renal cell carcinoma, and HPV-positive head and neck cancer.
The pharmacokinetic profile of SNS-101 supports once every three-week dosing, showing linear elimination kinetics and dose-proportional increases in exposure. The ongoing dose expansion portion aims to enroll more patients, with initial data anticipated by the end of 2024.
EGLE Therapeutics announced the appointment of Pejvack Motlagh, MD, MSc, as Chief Medical Officer and John Celebi, as Independent Board Member. Dr. Motlagh's expertise will drive clinical strategy and development, focusing on advancing the company's pipeline in oncology and auto-immunity. Mr. Celebi brings over 25 years of experience in building biotechnology companies. His extensive background includes serving as President and CEO of Sensei Biotherapeutics (NASDAQ: SNSE) and holding leadership positions in various biotech firms.
Sensei Biotherapeutics, Inc. reported financial results for Q1 2024 and recent business highlights, including clinical trial progress, upcoming data presentations, and a strong balance sheet with cash runway into Q4 2025.
